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Natural interferon-producing cells (IPCs) are found in peripheral lymph nodes (PLNs), where 
they support NK cell, T cell, and B cell responses to pathogens. However, their route of entry 
and the adhesive mechanisms used to gain access to PLNs remain poorly defined. We report 
that IPCs can enter PLNs via a hematogenous route, which involves a multistep adhesive 
process, and that transmigration is enhanced by inflammation. Results indicate that L-selectin 
on IPCs is required for efficient attachment and rolling on high endothelial venules in vivo 
in both nonstimulated and inflamed PLNs. IPCs, however, also possess functional ligands for 
E-selectin that contribute to this process only in the latter case. In conjunction with 
selectin-mediated adhesion, both 
 
 
 
1
 
- and 
 
 
 
2
 
-integrins participate in IPC attachment to the 
inflamed vessel wall, whereas chemotaxis relies in part on the chemokine receptor CCR5. 
Identification of the adhesive machinery required for IPC trafficking into PLNs may provide 
opportunities to regulate immune responses reliant on the activity of these cells.
 
Natural IFN-producing cells (IPCs), also called
plasmacytoid DCs, are a rare subset of cells
that are found in both circulating blood and
secondary lymphoid organs (1, 2). They are
believed to be important in host defense
against viral infections because of their ability
to detect DNA and RNA viruses through
Toll-like receptor (TLR) 9 and TLR7 (3) and
their capacity to secrete high levels of type I
IFN (4–6), IL-12 (5–7), and proinflammatory
chemokines (8–11). Collectively, the cytokine
responses of IPCs enhance NK cell and CD8
 
 
 
T cell responses to viral infections (12, 13) and
protect DCs from the cytopathic effect of viruses
(5, 10, 12). In addition, IPCs express MHC
class II molecules and can present antigens,
stimulating T cell proliferation and differen-
tiation in vitro and in vivo (1, 2). IPCs also
promote the differentiation of B cells into
plasma cells by secreting IFN-
 
 
 
 and IL-6 (14).
Thus, IPCs may considerably contribute to
antiviral responses not only through cytokine
production but also by promoting T cell and B
cell responses to pathogens.
To support the various innate and adaptive
responses to viruses, IPCs must accumulate in
secondary lymphoid organs, such as peripheral
LNs (PLNs), where they can subsequently
interact with NK cells, T cells, and B cells. To
do so, it would be anticipated that IPCs must
undergo a well-orchestrated series of adhesive
interactions with high endothelial venules
(HEVs), as shown for T lymphocytes. In regards
to the latter, L-selectin initiates this process by
facilitating their capture by and subsequent
rolling on HEVs through interactions with its
endothelial ligand known as peripheral node
addressin (PNAd), which is a mixture of gly-
cosylated and sulphated sialomucins that are
constitutively expressed on the surface of these
HEVs (15–17). As a result, T lymphocytes are
brought into close apposition with the vessel
wall, which permits the engagement of the
secondary adhesion receptors such as the
 
 
 
2
 
-integrin, lymphocyte function-associated
antigen (LFA)–1, that binds to intercellular
adhesion molecules (ICAMs) expressed on
endothelium (18). This results in the cessation
of rolling, as LFA-1 is responsible for mediating
the firm attachment of T cells. Typically, this
 
 
 
2
 
-integrin exists in an inactivated state on
circulating lymphocytes. Its ability to interact
with ICAMs relies on G
 
 
 
i-linked intracellular
signaling events that result from the engagement
of chemokine receptors such as CCR7 (19)
with its cognate ligands CCL21 (20, 21) and,
possibly, CCL19 (22, 23). This results in alter-
ations in conformation and surface distribution
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of LFA-1 that facilitate binding (24). Subsequent transmigra-
tion of T lymphocytes also relies, in part, on the interaction
between CCR7 and these chemokines. In contrast, CXCR3
and CCR5 are preferentially expressed on T cell subsets that
are recruited to sites of inflammation, and ligands for these
receptors are known to be produced in PLNs in response to
specific antigenic stimuli (25, 26).
IPCs express several adhesion molecules and chemokine
receptors on their surface that could promote interactions
with HEVs and support their emigration from the blood into
PLNs. For instance, L-selectin is constitutively expressed on
these cells and has been indirectly implicated in supporting
IPC trafficking into secondary lymphoid organs. This is sug-
gested by the considerable reduction in number of these cells
in noninflamed LNs obtained from L-selectin–deficient mice
(27). However, the overall cellularity of L-selectin
 
 
 
/
 
 
 
 PLNs
is dramatically reduced, which may affect chemokine pro-
duction and, thus, IPC recruitment (28, 29). Moreover, this
observation is contradicted in part by in vivo experiments in
which antibody blockade of L-selectin function only inhib-
ited mobilization of DC precursors into the circulation of
mice and not the trans-HEV migration of these cells (30). In
fact, minimal L-selectin–dependent adhesion of IPCs to non-
inflamed HEVs was reported. In regards to firm adhesion,
IPCs do express 
 
 
 
1
 
- and 
 
 
 
2
 
-integrins, but no in vivo infor-
mation exists regarding the specific integrin receptors that are
required for this process. Migration of these cells into PLNs,
which has been previously evaluated under inflammatory
conditions, is believed to solely involve CXCR3 (30). How-
ever, a role for other chemokine receptors known to partici-
pate in cell trafficking to sites of inflammation such as CCR5,
which is also expressed on IPCs (30), remains to be deter-
mined. The multiplicity of chemokine receptors involved in
IPC migration is also underscored by a recent study showing
that engagement of TLR7 and TLR9 and production of
IFN-
 
 
 
 induce IPC responsiveness to CCR7 ligands (31).
To establish whether IPC accumulation in PLNs can oc-
cur via a hematogenous route and to elucidate the potential
Figure 1. Surface expression of homing molecules on bloodborne- 
and BM-derived murine IPCs. IPCs were identified in either heparinized 
whole blood or BM cultured with Flt3 ligand by gating on B220 /440c  
cells. Note that these cells were also CD11c  and CD11blow/  (not depicted). 
Both bloodborne and culture-derived IPCs express L-selectin, PSGL-1, 
LFA-1, VLA-4, and CXCR3. KO controls are also shown for L-selectin and 
CXCR3 for comparison. (B) Representative dot plot demonstrating the 
presence of IPCs in PLNs of germ-free mice as compared with those 
housed solely in a barrier facility. The percentage of cells in each gate is 
indicated. 
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adhesive mechanisms involved in this process, we used intra-
vital microscopy (IVM) to study the behavior of murine
IPCs in the microvasculature of subiliac LNs in the absence
or presence of an inflammatory stimulus. The results of this
study provide the first direct evidence that IPCs can emi-
grate from the blood into PLNs by interacting with HEVs
through a coordinated multistep process and delineate im-
portant differences from previous studies regarding the mo-
lecular requirements for IPC trafficking.
 
RESULTS
Expression of adhesion molecules on BM-derived 
and bloodborne IPCs
 
After developing in the BM, IPCs reach the bloodstream
and presumably continue to circulate until constitutive and/
or inflammatory signals guide them into secondary lymphoid
organs. Given this, bloodborne IPCs would be most appro-
priate for investigating the molecular mechanisms by which
these cells are recruited to LNs. However, as the number of
circulating IPCs in the blood are extremely low, represent-
ing 
 
 
 
0.1–0.2% of total peripheral blood leukocytes, it is vir-
tually impossible to purify sufficient quantities to directly
study their behavior in HEVs of PLNs by IVM. Likewise,
isolating IPCs from spleen and LNs is not only hampered by
the very small number of such cells in secondary lymphoid
organs (32), but expression and/or activation of adhesion
molecules may differ among blood, spleen, and LN IPCs. A
reasonable alternative to bloodborne IPCs are those derived
from mouse BM (BM-IPCs). Substantial quantities of these
cells can be grown in vitro from BM precursors with Flt3
ligand (33, 34) and sorted to 90–95% purity. Importantly,
these cells appear to function analogously to bloodborne
IPCs in regards to type I IFN production and in response to
viral challenge (1, 2). One caveat to the use of BM-derived
cells in exploring the ability of IPCs to traffic into PLNs is
that they must express the identical adhesion molecules and
chemokine receptors as their bloodborne counterparts.
Thus, we stained IPCs from culture and whole blood with a
panel of antibodies specific for adhesion molecules that may
participate in trafficking to unperturbed or inflamed PLNs
(Fig. 1 A). In regards to adhesion molecules that could po-
tentially promote the attachment and rolling of these cells on
HEVs constitutively and/or in response to inflammatory
stimuli, both BM-derived and bloodborne IPCs expressed
L-selectin and the E- and P-selectin ligand, PSGL-1. More-
over, these two cell populations also expressed the 
 
 
 
1
 
- and
 
 
 
2
 
-integrin receptors CD49d/CD29 (VLA-4) and CD11a/
CD18 (LFA-1), respectively, which are required for firm ad-
hesion. In regards to chemokine receptors, both BM- and
blood IPCs are known to express CCR5 and CXCR3, with
the latter being implicated in the transmigration of IPCs into
PLNs (8, 30). These results, together with previously pub-
lished reports, demonstrate that BM-IPCs display an array of
homing molecules that closely resembles those on their
bloodborne counterparts. Moreover, identical adhesion mol-
ecules have been identified on human blood IPCs (1, 2),
suggesting that the molecular requirements for IPC traffick-
ing to PLNs may be similar in both humans and mice.
 
L-Selectin mediates attachment and rolling of IPCs 
on HEVs of PLNs
 
To establish whether or not IPC accumulation in PLNs can
occur via a hematogenous route, we assessed the in vivo be-
havior of purified murine BM-IPCs stained in vitro with the
intracellular fluorophor 2
 
 
 
7
 
 
 
,-bis-(2-carboxyethyl)-5(and 6)
carboxyfluorescein
 
 
 
(BCECF). Labeled IPCs were injected
retrograde through the contralateral femoral artery of mice
and observed by epifluorescent IVM during their passage
through the microcirculation of noninflamed subiliac LNs.
Indeed, IPCs were capable of attaching to and rolling on the
luminal surface of HEVs (
 
 
 
60%) in a manner previously re-
ported for T lymphocytes (Fig. 2 A) (18). Moreover, BM-
IPCs used L-selectin in supporting this interaction, as a sub-
stantial percentage of cells derived from the BM of animals
deficient in this adhesion molecule failed to attach and roll
under identical conditions (
 
 
 
90%). Purified cells activated
Figure 2. IPC roll and stick but minimally transmigrate across HEVs 
in noninflamed PLNs. BCECF-labeled IPCs, generated from the BM of WT 
or L-selectin /  mice, were injected into the microcirculation of a nonin-
flamed PLN, and the (A) percent rolling fraction and (B) percent sticking 
fraction were determined by fluorescence microscopy (20 ) in identical 
fields of view. n   number of mice per venules analyzed. Data are shown 
as mean   SE. (C) Representative micrographs of HEVs in PLNs at 6, 8, 10, 
or 12 h after injection of labeled IPCs (10 ). The skin overlying the subiliac 
LN was initially left intact until the designated time of viewing. Data are 
representative of three individual experiments. (D) Representative dot plot 
to evaluate the accumulation of BCECF-labeled WT IPCs in two noninflamed 
subiliac PLNs at 6 or 12 h after injection, as determined by flow cytometry 
(2 vs. 1 BCECF-labeled cells/105 total events, respectively). 
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with CpG oligonucleotides 2 h before administration also did
not notably interact with HEVs, which was consistent with
their down-regulation of L-selectin expression (unpublished
data). We conclude from these observations that circulating
BM-derived IPCs can be recruited to HEVs of noninflamed
PLNs through an adhesive event requiring L-selectin, as de-
scribed for naive T cells. In regards to their bloodborne
counterparts that express lower levels of this adhesion mole-
cule, it is conceivable that such interactions may be curtailed.
However, this may not prevent the constitutive trafficking of
endogenous IPCs into PLNs, as these cells can also be found
in PLNs of germ-free mice (Fig. 1 B). Thus, in the absence of
any external inflammatory stimuli that could alter adhesion
molecule expression on IPCs or HEVs, L-selectin would be
the primary adhesion receptor responsible for the attachment
and rolling of these cells on this specialized vascular endothe-
lium. This is consistent with a previous report that, under
noninflamed conditions, PLNs in mice lacking L-selectin
have reduced numbers of IPCs (27). Moreover, we have
found that the ratio of IPCs to myeloid DCs in the LNs of
these animals to be reduced by 
 
 
 
50% (unpublished data).
 
IPCs firmly adhere to noninflamed HEVs but undergo limited 
transendothelial cell migration
 
In addition to selectin-mediated attachment and rolling, cir-
culating hematogenous cells such as lymphocytes must be
able to stably interact with HEVs, a prerequisite to chemoat-
tractant-induced migration. To determine if IPCs are capa-
ble of firmly adhering to this specialized endothelium, we
measured the fraction of rolling cells that subsequently be-
came stationary on HEVs for 30 s. 
 
 
 
50% of all rolling IPCs
eventually stuck to HEVs, with the remainder exhibiting
transient arrest and release (Fig. 2 B). To test whether IPCs
that became stably adherent to the endothelium eventually
migrate into the lymphoid tissue underlying HEVs, we fol-
lowed IPC extravasation by IVM over a period of 12 h. WT
animals were injected with BCECF-labeled cells via the
femoral artery, and the nonmanipulated subiliac PLNs were
exposed and viewed by IVM only at 6-, 8-, 10-, or 12-h
time points. This was done to prevent possible alterations in
IPC trafficking caused by the effect of prior tissue manipula-
tion, which may impair the flow of blood and lymphatic
fluid. Although cells were still firmly attached to HEVs at
6 h, no substantial amount of transmigration was observed at
later time points (Fig. 2 C). In fact, continuous viewing of
IPC behavior in surgically exposed HEVs of PLNs from 10
min to 6 h after infusion revealed that the majority of adher-
ent cells eventually detached from HEVs and returned back
into the circulation (unpublished data). Moreover, retro-
grade injection of BCECF-labeled cells into the femoral ar-
teries of mice and subsequent harvesting of two unperturbed
subinguinal PLNs at 6 and 12 h yielded little evidence of
IPC accumulation, as demonstrated by flow cytometry (Fig.
2 D). Thus, unlike the constitutive trafficking of lympho-
cytes, IPC migration into noninflamed LNs appears to be
limited under steady-state conditions in our intravital system,
which is reflective of their overall small numbers in nonin-
flamed PLNs (
 
 
 
0.1–0.5% of all cells). This is also consistent
with the relatively slow turnover of these cells in nonin-
flamed LNs draining cutaneous tissues as compared with T
lymphocytes (35).
Figure 3. IPC transmigration into PLNs is enhanced by inflammation. 
Representative micrographs depicting (A) HEVs alone (panel 1, 10 ), HEVs 
10 min after injection of BCECF-labeled WT IPCs (panel 2, 10 ), HEVs 12 h 
after injection of labeled cells (panel 3, 10 ), and an enlarged section of 
PLNs (panel 4, 20 ). (B) Representative micrographs of an inflamed PLN 
after i.v. injection of 150 kD FITC–dextran and 12h after injection of BCECF-
labeled WT IPCs (panel 1, 40 ). Lines demarcate lateral borders of the 
lumenal compartment. A micrograph demonstrating IPC transmigration at 
12 h without prior surgical intervention is shown for comparison (panel 2). 
PLN inflammation was induced by injection of Mtb as described in Materials 
and methods. (C) Representative dot blot to evaluate the accumulation of 
BCECF-labeled WT IPCs in inflamed subiliac PLNs at 6 or 12 h after injection, 
as determined by flow cytometry (2 vs. 13 BCECF-labeled cells/105 total 
events, respectively). (D) Representative micrographs of an inflamed PLN 
after i.v. administration of 150 kD FITC–dextran at 10 and 30 min after 
injection of BCECF-labeled T cells (panels 1 and 2, respectively; 40 ). 
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IPCs transmigrate into inflamed PLNs
 
Although IPCs did not show remarkable transendothelial mi-
gration under noninflamed conditions in our system, they
clearly are capable of emigrating from the blood into in-
flamed PLNs. In fact, it has been well established that these
cells are abundant in inflamed LNs of patients with particular
infections or autoimmune diseases, as well as in draining LNs
found at sites of inflammation in mice (30, 36, 37). More-
over, we have previously shown that repeated s.c. injections
of heat-killed 
 
Mycobacterium tuberculosis
 
 (
 
Mtb
 
) into the mouse
hind legs over a 72-h period of time leads to considerable re-
cruitment of IPCs in the draining LNs as compared with the
control, although the route of entry of these cells remained
elusive (37). Therefore, we used this model to determine
whether IPC recruitment into PLNs via a hematogenous
route is enhanced by inflammation. Labeled IPCs were in-
fused 24 h after the last of two injections of 
 
Mtb, 
 
and their ad-
hesive behavior was followed by IVM during the initial in-
jection and for the subsequent 24 h. Direct observation of
fluorescently labeled cells in HEVs of 
 
Mtb
 
-treated mice re-
vealed that firmly adherent cells (Fig. 3 A, panel 2) did trans-
migrate into PLNs, an event that occurred maximally at 12 h
(panels 3 and 4). This was evident upon the i.v. administra-
tion of FITC–dextran that demarcated the boundaries of the
HEV lumen (Fig. 3 B, 1). Moreover, transmigration under
these conditions did not appear to be influenced by prior sur-
gical manipulation of PLNs, as this process was still evident
upon viewing of unperturbed LNs 12 h after the infusion of
IPCs (Fig. 3 B, panel 2). Similarly, retrograde injection of
BCECF-labeled cells into the femoral arteries of mice and the
subsequent harvesting of inflamed subinguinal PLNs at 6 and
12 h demonstrated considerable IPC accumulation only at
the latter time point (sixfold increase), as demonstrated by
flow cytometry (Fig. 3 C). This delay in IPC migration did
not appear to be caused by surgical manipulation of the
PLNs, as migration of purified T cells was observed to occur
within 10 min after injection (Fig. 3 D).
 
L- and E-selectin are required for IPC rolling on 
inflamed HEVs
 
After establishing that inflammation enhances the accumula-
tion of IPCs in PLNs, we next evaluated whether the attach-
ment and rolling of these cells on HEV in 
 
Mtb
 
-treated mice
relied solely on L-selectin. 
 
 
 
50% of circulating BM-IPCs
attached and rolled on HEVs contained within the microcir-
culation of inflamed LNs (Fig. 4 A), paralleling their behav-
ior under noninflammatory conditions. In contrast, a defi-
ciency of L-selectin resulted in only a partial reduction in the
rolling fraction of IPCs (
 
 
 
50%) without affecting firm adhe-
sion, suggesting that other adhesive interactions may
contribute to this process during inflammation. A potential
candidate includes E-selectin, which is known to be up-reg-
ulated on the surface of HEVs in response to inflammatory
stimuli (38). However, it is not known whether selectin
ligands expressed on IPCs, such as PSGL-1, are functional
and can thus contribute to their recruitment to inflamed
PLNs. As we established that our BM-derived IPCs do ex-
press high levels of PSGL-1 (Fig. 1), it was also necessary to
determine if they can interact in flow with purified selectin
molecules. Indeed, these cells can bind to surface-immobi-
lized E- or P-selectin under hydrodynamic conditions in
vitro (Fig. 4 B). Consistent with these findings was a 
 
 
 
90%
reduction in the attachment and rolling of L-selectin
 
 
 
/
 
 
 
IPCs in HEVs of mice deficient in E-selectin as compared
with WT control cells and PLNs (rolling fraction of 4.2 
 
 
 
3.4% vs. 48.7 
 
 
 
 14.4%, respectively; Fig. 4 A). Moreover,
these cells were not capable of becoming firmly adherent to
HEVs and, thus, could not undergo transmigration (unpub-
lished data). In contrast, the absence of E-selectin alone did
not significantly (P 
 
 
 
 0.05) impair this process (rolling frac-
tion of 44.7 
 
 
 
 9.5%), demonstrating the importance of
L-selectin–dependent interactions. Of note, CpG-activated
IPCs, which down-regulate L-selectin, are also capable of
interacting with and transmigrating across HEVs of inflamed
PLNs (unpublished data). Thus, the contribution of L-selec-
tin is not absolute in regards to IPC recruitment under these
conditions. We conclude that IPC attachment and rolling
under these inflammatory conditions rely on interactions
Figure 4. L- and E-selectin are required for IPC attachment and 
rolling on HEVs of inflamed PLNs. BCECF-labeled IPCs generated from 
the BM of WT or L-selectin /  mice were injected through the femoral 
artery of WT or E-selectin /  animals, and the rolling fraction was 
quantified as they passed through HEVs in inflamed PLNs. Data are shown 
as mean   SE. *, P   0.05; n   number of mice per venules analyzed. 
(B) Attachment of WT IPCs to surface-immobilized E- or P-selectin Ig 
chimeras at a wall shear rate of 200 s-1. Adhesion to the  2-integrin ligand 
ICAM-1–Ig chimera is shown as a negative control. Results represent the 
mean   SE for three experiments performed in duplicate. 
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mediated by L-selectin and glycoproteins on IPCs, with
their cognate ligands PNAd and E-selectin on HEVs.
 
Firm adherence of IPCs to inflamed PLNs/HEVs involves 
 
 
 
1
 
- and 
 
 
 
2
 
-integrins
 
It has been established that firm adhesion of lymphocytes to
HEVs is mediated by the 
 
 
 
2
 
-integrin LFA-1 (CD11a/CD18)
(18). As IPCs also express this adhesion molecule (Fig. 1), it
is reasonable to assume that LFA-1 would serve an identical
function in supporting the firm adhesion of these cells to in-
flamed HEVs. In contrast to T lymphocytes, firm adhesion
of IPCs did not appear to require this adhesion molecule, as
BM cells derived from animals deficient in this 
 
 
 
2
 
-integrin
stuck to inflamed HEVs at levels comparable with those of
WT control cells (48.8 
 
 
 
 12.4% vs. 53.1 
 
 
 
 16.8%, respec-
tively; Fig. 5 A). Among potential secondary adhesion re-
ceptors that may also participate in firm adherence of IPCs
to inflamed HEVs, the 
 
 
 
1
 
-integrin VLA-4 is a likely candi-
date, as it is expressed on this subset of DCs (Fig. 1). More-
over, the counterligand for the former, vascular endothelial
adhesion molecule (VCAM)–1, is up-regulated on HEVs
during inflammation (39). Despite the i.v. administration of
a function-blocking antibody to mouse VCAM-1, however,
rolling IPCs continued to undergo firm adhesion at levels
comparable with both WT and LFA-1
 
 
 
/
 
 
 
 cells (43 
 
 
 
 4.5%;
Fig. 5 A). In contrast, LFA-1–deficient IPCs injected into
WT animals pretreated with the VCAM-1 antibody were
unable to firmly adhere to inflamed HEVs. However, IPC
attachment and rolling was unaffected under these condi-
tions (Fig. 5 B). Thus, both 
 
 
 
1
 
- and 
 
 
 
2
 
-integrins contribute
to the stable attachment of IPCs to HEVs in inflamed PLNs.
 
The role of CCR5 versus CXCR3 in IPC transmigration
 
IPCs are known to express multiple chemokine receptors,
including CCR5 and CXCR3 (30). Moreover, it has been
shown that ligands for these receptors (i.e., CCL3, CCL4,
CCL5, and CXCL9) are produced in the inflamed LNs of
humans and/or mice (25, 26, 30). In fact, it has been sug-
gested that CXCR3 is the major chemokine receptor that
supports IPC transmigration into the inflamed PLNs of mice
(30). To confirm this finding and elucidate the role of other
chemokine receptors in this process, we studied the interac-
tion of cells deficient either in CXCR3 (40) or CCR5 (41)
with HEVs of inflamed PLNs. In contrast to this previous
study (30), CXCR3
 
 
 
/
 
 
 
 IPCs were able to transmigrate
across HEVs, with the results consistent in four individual
experiments (Fig. 6 A, panels 1–4). The absence of CCR5
on purified cells, however, did impede their ability to trans-
migrate under identical conditions. IPCs either remained
within the lumen of HEVs (Fig. 6 B, panels 1 and 2) or were
not present at all (panels 3 and 4). Confirmation that IPCs do
respond to ligands for CCR5 is demonstrated by their ability
to transmigrate across a bare filter insert in response MIP-1
 
 
 
and regulated on activation, normal T cell expressed and se-
creted (RANTES; Fig. 6 C).
To further demonstrate that IPCs do indeed use a G pro-
tein–coupled receptor to undergo transmigration, we eval-
uated the ability of pertussis toxin (PTX), an inhibitor of
G
 
 
 
i-linked signal transduction pathways (42), to prevent ex-
travasation of these cells into PLNs. Indeed, PTX treatment
of IPCs did prevent their transmigration into inflamed LNs
(Fig. 6 D, panel 2), supporting a role for this signal transduc-
tion pathway in this process. Further evidence is provided by
the ability of this toxin to abrogate IPC chemotaxis in vitro
(Fig. 6 D).
 
DISCUSSION
 
Our findings provide the first direct demonstration that IPCs
are recruited from the blood into PLNs through a multistep
process that involves rolling, firm adhesion, and transmigra-
tion across HEVs, the latter event being enhanced by inflam-
mation. This observation is paramount to deciphering our
previous results using the IPC-specific mAb 440c, which en-
abled us to detect by immunohistology an increase in IPC
numbers in PLN draining sites of inflammation (37). As these
cells possess the adhesion molecules and chemokine receptors
necessary to support trafficking into PLNs, it is highly proba-
ble that the enhanced localization of IPCs in these secondary
lymphoid organs is caused by their recruitment from the cir-
culation rather than from proliferation of resident cells in re-
sponse to inflammatory stimuli. Thus, it appears that a multi-
Figure 5.  1- and  2-integrins on IPCs participate in firm adhesion. 
The percent sticking fraction of WT or LFA-1 /  IPCs in HEVs of inflamed 
PLNs in the absence or presence of the VCAM-1 function blocking F(ab )2 
M/K-2.7 was evaluated during their initial passage through the microcir-
culation. Data are shown as mean   SE. n   number of mice per venules 
analyzed. (B) The percent rolling fraction of IPCs under the identical 
conditions.JEM VOL. 202, September 5, 2005 693
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step adhesive process akin to that of T lymphocytes is key to
regulating the localization of IPCs in PLNs.
Importantly, the use of IVM, rather than immunohistol-
ogy, has enabled us to identify the adhesion molecules that
contribute to IPC trafficking into PLNs in flowing blood, of
which E-selectin and VCAM-1 are only expressed on HEVs
in response to inflammatory stimuli. This is in contrast to the
constitutive expression of the L-selectin ligand known as
PNAd. Thus, these cells are well suited for both constitutive
and inflammation-directed homing to PLNs, as IPCs express
both L-selectin and functional ligands for E-selectin on their
surface (i.e., PSGL-1). Similarly, they bear the appropriate
set of integrin receptors (i.e., LFA-1 and VLA-4) required
for entry into these secondary lymphoid organs under the
specified conditions. Although evidence exists suggesting
that IPCs may constitutively home to LNs, as is the case for
naive T lymphocytes, the more robust accumulation of these
cells in response to an inflammatory stimulus is also consis-
tent with their ability to regulate an adaptive immune re-
sponse under such conditions. This would explain why IPCs
are most abundant in the T cell area of inflamed secondary
lymphoid organs in the human and mouse, particularly
around HEVs (30, 36, 37). Moreover, the requirement for
CCR5 to promote IPC migration into inflamed PLNs is
consistent with the fact that ligands for this chemokine re-
ceptor (i.e., CCL3, CCL4, and CCL5) are only expressed
under such conditions. In fact, these chemokines are known
to contribute to the trafficking of T cell subsets into LNs
during an immune response (25). That said, the presence of
IPCs in noninflamed PLNs of normal and germ-free mice,
albeit  0.1–0.5% of the total population of cells, suggests
that constitutive trafficking from the blood into LNs can oc-
cur. Although in our study CXCR3 was not required for
IPC migration in response to Mtb, it is possible that in differ-
ent inflammatory conditions, such as those reported by Yo-
neyama et al. (30), CXCR3 and CCR7 may play an impor-
tant role because of the induction of CXCR3 ligands and
up-regulation of CCR7 (31). This would be consistent with
a previous study demonstrating that the particular chemo-
kine produced in inflamed LNs affected the prevailing dis-
ease state (26). For instance, CXCR3 ligands were shown to
drive IPC migration into all LNs after i.v. injection of Propi-
oni bacterium acnes, which can induce systemic inflammation
as well as up-regulation of CCR7 on this cell type (30).
Moreover, CXCR3 ligands have been shown to promote
IPC migration into LNs draining a cutaneous HSV-1 infec-
tion (30). Similarly, murine CMV infection and systemic in-
jection of TLR7 and TLR9 ligands induced migration and
clustering of splenic plasmacytoid DCs in the spleen mar-
ginal zone. This migration was dependent on CXCR3
Figure 6.   IPC transmigration across HEVs in inflamed PLNs is 
CCR5-dependent.  (A) Representative micrographs of HEVs in inflamed 
PLNs 12 h after injection of CXCR3 /  IPCs in the absence of (panel 1, 
10 ) or after i.v. administration of FITC–dextran to delineate the vascular 
compartment (panel 2, 10 ; panels 3 and 4, 20 ).  All panels are from 
individual animals (n   4).  (B) Representative micrographs of HEVs in 
inflamed PLNs 12 h after injection of CCR5 /  IPCs in the absence of 
(panels 1, 3, and 4; 10 ) or after i.v. administration of (panel 2, 10 ) 
FITC–dextran to delineate the vascular compartment.  All panels are 
from individual animals (n   3).  (C) Migration of BM-derived IPCs across 
bare transwell filters in response to fractalkine, MIP-1 , or RANTES.  
(D) Representative micrographs depicting the same HEV either 10 min 
(panel 1, 10 ) or 12 h (panel 2, 10 ) after the injection of BCECF-labeled 
WT IPCs pretreated with 100 ng/ml PTX. The effect of 100 ng/ml PTX on 
SDF-1–induced chemotaxis in an in vitro transwell assay system is shown 
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ligands induced by type I IFNs during inflammation. In this
system, type I IFN was also required for up-regulation of
CCR7 on IPCs, which allows them to migrate in response
to CCR7 ligands (31).
It is reasonable to speculate that circulating IPCs can use
the same adhesion and chemokine receptors as described
here to accumulate in inflamed tissues other than PLNs. For
instance, IPCs are not normally found in skin, but readily ac-
cumulate in this organ system during inflammation as a result
of autoimmune diseases such as systemic lupus erythematosus
(43). Moreover, E-selectin and VCAM-1 are coexpressed on
vessels contained within dermal lesions associated with this
disease state, as well as the chemokine chemerin (44, 45).
Most recently, IPCs have been shown to undergo chemo-
taxis in response to chemerin (46), a novel protein identified
as the natural ligand of ChemR23, which is a G protein–
coupled receptor (45, 47). Thus, identification of the adhe-
sive pathways involved in IPC recruitment by inflamed
tissues such as LNs or skin may provide an opportunity to
regulate the trafficking pattern of these cells such that one
may modulate the immune response.
MATERIALS AND METHODS
Reagents and mice. Flt3 ligand and Mtb were purchased from R&D Sys-
tems and Difco Laboratories, respectively. Murine SDF-1, MIP-1 ,
RANTES, and fractalkine were obtained from PeproTech, and CpG oligo-
nucleotide 2216 was obtained from QIAGEN. Murine E-selectin, human
P-selectin, or human ICAM-1 expressed as Fc chimeric proteins were ob-
tained from R&D Systems, Genetics Institute, or ICOS Corp., respectively.
PTX was purchased from Sigma-Aldrich. L-selectin /  mice were obtained
from M. Siegelman (University of Texas Southwestern Medical Center,
Dallas, TX), CXCR3 /  mice were provided by C. Gerard (Harvard Med-
ical School, Boston, MA), and germ-free mice were obtained from J. Gor-
don (Washington University School of Medicine, St. Louis, MO).
Antibodies. The following mAbs to mouse proteins were purchased from
BD Biosciences: CD62L, CD162 (PSGL-1), CD29, CD49d (VLA-4),
CD11b (Mac-1), CD11c (p150,95), and B220. Function-blocking anti–
mouse VCAM-1 (M/K-2.7) antibody was purchased from the American
Type Culture Collection. mAb 440c and anti-CXCR3 antibody (provided
by R.D. Schreiber, Washington University School of Medicine, St. Louis,
MO) have been previously described (8, 37, 45, 47).
Preparation of cells. Murine BM cells from WT C57BL/6, L-selectin / ,
CXCR3 / , CCR5 / , or LFA-1 /  mice were cultured in 10 ng/ml
Flt3 ligand at 2–4   106 cells/ml for 9–10 d (8, 34). IPCs were isolated by
magnetic cell sorting (MACS; Miltenyi Biotec) by depletion of CD19  cells
followed by enrichment of B220  cells. Purity, as measured by flow cytom-
etry, was  95% B220 , CD19 , CD11c , CD11blow/ , and 440c . Cells
were stimulated with 6  g/ml CpG oligonucleotide 2216 for 2 h where in-
dicated in the figures. T cells were purified from PLNs of mice by negative
selection using magnetic cell sorting for B220  cells. Flow-through material
was  90% for CD3 .
Flow cytometry. For evaluating adhesion molecule expression on BM-
and blood IPCs, we performed three-color analysis using (a) allophycocya-
nin- or PE-conjugated 440c; (b) FITC–B220 or PE–B220; or (c) PE–
CD62L, PE–CD162, biotinylated LFA-1, biotinylated CD29, biotinylated
CD49d, or FITC–CXCR3. For determination of IPC trafficking into PLNs,
inflamed and noninflamed subinguinal LNs were harvested bilaterally, di-
gested with collagenase D for 1 h at 37 C, and stained with 440c–biotin,
B220–PE, and propidium iodide (PI). The entire cell suspension was ana-
lyzed by flow cytometry. A gate was set on live cells (PI negative). All sam-
ples were analyzed on a flow cytometer (FACSCalibur; BD Biosciences).
Chemotaxis assay. Chemotaxis was measured in a 2-h transwell migra-
tion assay using 24-well chambers with 5- m pores (Costar Transwell;
Corning Costar). 100 ng/ml recombinant SDF-1, 10 ng/ml MIP-1 , 100
ng/ml RANTES, or 100 ng/ml fractalkine was added to the lower wells in
600  l of chemotaxis medium (RPMI 1640 with 1% human serum albu-
min), and 2   105 cells in 100  l were added to the Transwell insert. Mi-
grated cells were counted by flow cytometry. Where indicated in the fig-
ures, cells were pretreated with 100 ng/ml PTX for 1 h at 37 C.
Induction of LN inflammation. Mice were injected with nonviable
desiccated Mtb s.c. in both hind legs (500  g/injection) at 72 and 24 h be-
fore the experiments. All animals were handled in accordance with policies
administered by the National Institutes of Health and the Washington Uni-
versity Institutional Animal Care and Use Committee.
Subiliac LN preparation and IVM. The left subiliac LN of anesthetized
mice was prepared for IVM as previously described (48). A polyethylene
catheter inserted in the right femoral artery was used for injection of cell
suspensions. IPCs were fluorescently labeled with BCECF (Molecular
Probes, Inc.) and visualized in the microcirculation of the node through a
10, 20, or 40  water immersion objective (Carl Zeiss MicroImaging, Inc.)
using an intensified camera (VE1000SIT; Dage-MTI) and epifluorescence
illumination (49). Rolling fraction (RF) was defined as the percentage of
cells that interact with a given region of venule as compared with the total
number of cells that enter that vessel (interacting and noninteracting) during
the same 1-min time period. The sticking fraction (SF), the percentage of
rolling IPCs that became stationary for a minimum of 30 s, was determined
during the same time period and segment of vessel. Some experiments in-
cluded injection of 10 mg/ml FITC–dextran (150 kD; Sigma-Aldrich) after
recordings of cell behavior to delineate the lumen of vessels. For experi-
ments evaluating IPC transmigration, the skin flap was sutured in place,
closing the wound, after collecting data on RF and SF, and subsequently re-
opened after a time period of 6, 8, 10, or 12 h for viewing by epifluorescent
IVM. For comparison purposes, fluorescently-labeled IPCs were inject
through the femoral catheter, and the skin overlying the subiliac LN was
left intact until the designated viewing times. For experiments evaluating
the role of  1-integrins in mediating IPC firm adhesion, a function-block-
ing F(ab )2 to 200  g mouse VCAM-1 was administer i.v. 1 h before the
injection of BCECF-labeled IPCs. Video images were recorded using a Hi8
VCR (Sony), and analysis was performed using a PC-based image analysis
system as previously described (50).
Laminar flow assays. For flow studies involving recombinant proteins,
polystyrene plates were coated overnight with PBS, pH 7.4, containing 100
 g/ml protein A (Sigma-Aldrich) at 4 C, washed, and incubated with E- or
P-selectin or ICAM-1–Fc chimeric proteins diluted to a concentration of
20  g/ml (PBS, 0.1% BSA, pH 7.4) for 2 h at 37 C (50). Nonspecific inter-
actions were blocked with PBS containing 50  g/ml rabbit Ig for 30 min at
37 C. 106 IPCs/ml (HBSS, 10 mM Hepes, 1 mM CaCl2, 0.5% BSA, pH
7.4) were infused over the selectin substrates that had been incorporated
into a parallel plate flow chamber (GlycoTech) at a shear rate of 200 s-1. IPC
accumulation was recorded on Hi8 videotape using an inverted microscope
(TE300; Nikon) with a plan 10  objective. The number of cells that at-
tached over 5 min was determined and expressed per unit area.
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